Eli Lilly’s bamlanivimab was the first antibody-drug the FDA authorized to treat COVID-19. Now, the Indianapolis pharma has data showing the therapy prevents symptomatic infections.
The catch? The data are limited to long-term care facilities, where vaccination is now underway—and despite their utility, antibody therapies are having a tough time catching on.
Check out this article published by Fierce Pharma right here.